Thymagen

What is it?

Thymagen is a synthetic dipeptide (Glu-Trp) framed as the short-peptide successor to Thymalin: same thymic/immune target as the original tissue extract, distilled down to two amino acids. It’s part of the second generation of the Khavinson bioregulator family — synthetic short peptides (di-, tri-, tetrapeptides) designed to reproduce the active fragment of the original organ-extract complexes. Site tier is Emerging (1 study, 0 human).

What does it do in my body?

Claimed mechanism: stimulates thymic epithelial-cell activity, supporting T-cell maturation and differentiation in the aging thymus — the same organ target as Thymalin, at a much more distilled molecular level.

This sits inside the broader Khavinson-family theoretical claim that short tissue-derived peptides can cross cell and nuclear membranes and modulate gene transcription in a tissue-specific way. Family-wide in-vitro work supports the underlying nuclear-penetration mechanism: short Khavinson peptides penetrate HeLa-cell nuclei and interact with DNA (Fedoreyeva et al. 2011, Biochemistry (Mosc), 22117547).

How can it help me?

• Where the science stands: Thin — site tier Emerging (1 study, 0 human); animal/in-vitro only

The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.

Is it dangerous? What are the side effects?

The reported adverse-event profile across the family is mild and uncommon in the Russian literature: occasional injection-site reactions, transient mild headache early in a cycle. No serious AEs documented at standard doses.

The real risk isn’t the molecule — it’s the supply chain. Khavinson-family peptides are the dominant gray-market counterfeit category in the peptide space. Buyers typically source these from forum links with no way to verify identity or purity, and counterfeit/mislabeled product is the most common failure mode for exactly these compounds. Third-party COA verification matters more here than for almost any other peptide class.

Regulatory status: Thymagen is research_only in the US — not FDA-approved for human use, sold as a research compound, not eligible for compounding. It is not a controlled substance. Note that the family prototype, Thymalin (and the related cortex peptide Cortexin), holds a clinical-use approval in Russia — that approval does not extend to Thymagen or to the US.

Part 1 — How to reconstitute it

What's used: bacteriostatic water (sterile, preserved water the powder is mixed with) and a separate, larger reconstitution syringe used only for mixing — not the small syringe used for administration.

The exact bacteriostatic-water volume and resulting concentration for Thymagen are covered in the dosing notes and the deeper-science view. The right volume depends on the vial size.

How it's mixed

• The vial is tilted and the bacteriostatic water is added slowly down the inside glass wall — not squirted straight onto the powder.
• It is swirled gently to dissolve. It is never shaken — shaking can damage the peptide.
• The reconstituted vial is stored refrigerated and out of light.
• Reconstituted peptides are commonly used within a few weeks, inside the beyond-use window the source specifies — that window varies by peptide.

The free reconstitution calculator does the concentration math for any vial size and water volume, including the equivalent units on an insulin syringe.

Part 2 — Typical dosing

Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.

Administration as reported. Reported practice is subcutaneous administration (into the fat just under the skin) using a 0.3 mL U-100 insulin syringe, with sites rotated.

Educational purposes only — this reflects what Russian-school protocols and the peptide community actually use, stated plainly; it is not medical advice.

There is no Western-validated dosing protocol for Thymagen. What exists is the Khavinson-school cycle pattern shared across the family:

• Cycle structure: a short course — typically 10–20 consecutive days — followed by a long rest, repeated 2–3 times per year. The framework claims effects persist 2–3 months past the end of a cycle — asserted by the Khavinson program, not independently confirmed.
• Dose: as a synthetic short dipeptide, community subcutaneous dosing converges around ~100–200 mcg/day over the 10–20 day cycle; some Khavinson-family short peptides are also sold as oral capsules or sublingual drops in the Russian retail market per-peptide specifics.
• Storage: lyophilized powder is stable cold; once reconstituted with bacteriostatic water, refrigerate and use within roughly 28 days.

Because per-peptide human dose-finding data doesn’t exist for this family, treat every number above as community/Russian-protocol convergence, not a validated dose.

Turning milligrams into syringe units. On a U-100 syringe, 100 units = 1 mL, so 1 unit = 0.01 mL. At a concentration of C mg/mL, a dose of D mg = D ÷ C mL = (D ÷ C) × 100 units. Example: at 5 mg/mL, a 0.5 mg dose = 0.1 mL = 10 units. The exact units depend on the vial's mg and the water volume used.

What should I avoid combining — and what's synergistic?

Thymagen doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.

Where do people source this?